<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03045445</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-2016-2830</org_study_id>
    <nct_id>NCT03045445</nct_id>
  </id_info>
  <brief_title>&quot;Double Low-Dose&quot; DECT for HCC Imaging</brief_title>
  <official_title>Comparison of Image Quality Between &quot;Double Low-Dose&quot; Dual Energy Liver CT and Standard Contrast Enhanced Liver CT in Patients at High-risk of HCC: Prospective, Randomized Single Center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philips Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: double low-dose protocol provide better lesion conspicuity than standard protocol
      CT in patients at high-risk of HCC.

      patients who are scheduled for CECT for HCC diagnosis or surveillance are eligible for this
      study and allocated to either standard protocol or double-low dose protocol using spectral CT
      with low radiation dose and low dose of contrast media, within clinically accpetable range.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 30, 2017</start_date>
  <completion_date type="Anticipated">December 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lesion conspicuity</measure>
    <time_frame>12 months after CT</time_frame>
    <description>qualitative conspicuity assessment of focal liver lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>image noise</measure>
    <time_frame>12 months after CT</time_frame>
    <description>qualitative analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>beam hardening artifact</measure>
    <time_frame>12 months after CT</time_frame>
    <description>qualitative analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatic artery conspicuity</measure>
    <time_frame>12 months after CT</time_frame>
    <description>qualitative analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>portal vein conspicuity</measure>
    <time_frame>12 months after CT</time_frame>
    <description>qualitative analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>image texture (plasticity)</measure>
    <time_frame>12 months after CT</time_frame>
    <description>qualitative analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall image quality</measure>
    <time_frame>12 months after CT</time_frame>
    <description>qualitative analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of hepatic artery anatomic variation</measure>
    <time_frame>12 months after CT</time_frame>
    <description>yes, no, indeterminate and if yes) describe the variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sensitivity to detect HCC</measure>
    <time_frame>18 months after CT</time_frame>
    <description>according to LI-RADS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radiation dose</measure>
    <time_frame>1 month after CT</time_frame>
    <description>CTDIvol, DLP, and effective dose</description>
  </secondary_outcome>
  <other_outcome>
    <measure>contrast media iodine amount</measure>
    <time_frame>1 month after CT</time_frame>
    <description>contrast media iodine amount</description>
  </other_outcome>
  <other_outcome>
    <measure>adverse effect</measure>
    <time_frame>1 month after CT</time_frame>
    <description>any adverse effect related with contrast media</description>
  </other_outcome>
  <other_outcome>
    <measure>Enhancement degree</measure>
    <time_frame>12 months after CT</time_frame>
    <description>HU in aorta, portal vein and liver parenchyma on each phase of CT</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>HCC</condition>
  <arm_group>
    <arm_group_label>Double Low-Dose protocol CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low radiation dose + low amount of iodine contrast media at spectral CT (Philips Healthcare)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard protocol CT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard protocol quadriphasic liver CT according to current liver CT protocol in our institution, at spectral CT (Philips Healthcare)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Double Low-Dose protocol CT</intervention_name>
    <description>Double low-dose protocol CT (Low radiation dose quadriphasic liver CT and low dose of iodine contrast media) at spectral dual energy CT scanner</description>
    <arm_group_label>Double Low-Dose protocol CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Standard protocol CT</intervention_name>
    <description>standard protocol CT (standard dose quadriphasic liver CT and standard dose of iodine contrast media) at spectral dual energy CT scanner</description>
    <arm_group_label>Standard protocol CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  high risk of HCC (chronic hepatitis B or C, or LC of any cause)

          -  signed informed consent

          -  scheduled for contrast enhanced liver CT for HCC surveillance or diagnosis

        Exclusion Criteria:

          -  no risk factor for HCC

          -  history of iodine hypersensitivity

          -  renal dysfunction (Estimated GFR &lt; 30mL/min/1.73m2) or on dialysis

          -  metformin medication within 48 hours

          -  any other contraindication of CE-CT

          -  BMI &gt; or = 30
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2017</study_first_submitted>
  <study_first_submitted_qc>February 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>CT</keyword>
  <keyword>dual energy</keyword>
  <keyword>low dose</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

